According to Larry Brown, CSO and executive vice-president of R&D at Noveome, “ST266 provides a potentially revolutionary new way of treating ophthalmic conditions by targeting the optic nerve ...
According to Larry Brown, CSO and executive vice president of R&D at Noveome, “ST266 provides a potentially revolutionary new way of treating ophthalmic conditions by targeting the optic nerve ...